X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used in the clinical development of CT1812, which is being evaluated in Phase II clinical trial studies for the treatment of Alzheimer’s disease.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Titan Partners Group
Deal Size: $11.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 14, 2024
Details:
The net proceeds will be used in the clinical development of CT1812, which is being evaluated in Phase II clinical trial studies for the treatment of Alzheimer’s disease.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Titan Partners Group
Deal Size: $11.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 11, 2024
Details:
CT1812 is an experimental orally delivered small molecule sigma-2 (σ-2) receptor modulator designed to penetrate the blood-retinal barrier and currently is in development for geographic atrophy secondary to dry age-related macular degeneration.
Lead Product(s): CT1812
Therapeutic Area: Ophthalmology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
CT1812 binds selectively to the sigma-2 receptor complex which is involved in the regulation of key cellular processes, that are damaged by toxic interaction with soluble beta amyloid oligomers and is currently in development for mild-to-moderate Alzheimer’s disease.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: Elayta
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
CT1812 binds selectively to the sigma-2 receptor complex which is involved in the regulation of key cellular processes, that are damaged by toxic interaction with soluble beta amyloid oligomers and currently in development for mild-to-moderate Alzheimer’s disease.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Aging
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
CT1812 binds selectively to the sigma-2 receptor complex which is involved in the regulation of key cellular processes, that are damaged by toxic interaction with soluble beta amyloid oligomers, oxidative stress and other stressors. In dry AMD, this results in vision loss.
Lead Product(s): CT1812
Therapeutic Area: Ophthalmology Product Name: CT1812
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
CT1812, binds selectively to the sigma-2 receptor complex which is involved in the regulation of key cellular processes that are damaged by toxic interaction with Aβ oligomers, oxidative stress, leading in cognitive impairment and alzheimer’s progression.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
CT1812 is an oral small molecule designed to penetrate the blood-brain barrier and bind selectively to the sigma-2 (σ-2) receptor complex. It is being developed for cognitive impairment and alzheimer’s disease progression.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
CT1812 is an oral small molecule designed to penetrate the blood-brain barrier and bind selectively to the sigma-2 (σ-2) receptor complex. CT1812 is an experimental candidate and has not been approved by the U.S. FDA or other regulatory agency.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
CT1812 is an experimental oral sigma-2 (σ-2) receptor modulator currently in Phase 2 clinical trials for both Alzheimer's disease and dementia with Lewy bodies (DLB).
Lead Product(s): CT1812
Therapeutic Area: Ophthalmology Product Name: CT1812
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
